Epithelioid sarcoma (ES) is a rare soft tissue neoplasm that usually arises in the distal extremities of young adults. ES presents a high rate of recurrences and metastases and frequently poses diagnostic dilemmas. We previously reported loss of tumor suppressor SMARCB1 protein expression and SMARCB1 gene deletion in the majority of ES cases. Unfortunately, no appropriate pre-clinical models of such genetic alteration in ES are available. In the present report we identified lack of SMARCB1 protein due to a homozygous deletion of exon 1 and upstream regulatory region in epithelioid sarcoma cell line VAESBJ. Restoration of SMARCB1 expression significantly affected VAESBJ cell proliferation, anchorage-independent growth and cell migration properties, thus supporting the causative role of SMARCB1 loss in ES pathogenesis. We investigated the translational relevance of this genetic background in ES and demonstrated that SMARCB1 ectopic expression significantly augmented VAESBJ sensitivity to gamma irradiation and acted synergistically with Flavopiridol treatment. In VAESBJ, both activated ERBB1/EGFR and HGFR/MET impinged on AKT and ERK phosphorylation. We demonstrated a synergistic effect of combined inhibition of these two receptor tyrosine kinases using selective small molecule inhibitors on cell proliferation. These observations provide definitive support to the role of SMARCB1 inactivation in the pathogenesis of epithelioid sarcoma and disclose novel clues to therapeutic approaches tailored to SMARCB1-negative ES.
INTRODUCTION

Epithelioid sarcoma (ES, International Classification of Diseases for Oncology code number
8804/3) is a rare mesenchymal neoplasm that displays variable epithelioid morphology, presents a high rate of recurrences and metastases and frequently poses diagnostic dilemmas (1) . It usually affects young adults and arises in the distal extremities (classic-type ES) or, more rarely, in proximal sites of the trunk (proximal-type ES). Proximal-type ES is more frequently associated with epithelioid or rhabdoid morphology and higher mitotic activity (2) .
The SMARCB1 gene located at 22q11 chromosomal region encodes for an invariant subunit of SWI/SNF chromatin remodeling complex and has been reported to act as a tumor suppressor gene in infantile malignant rhabdoid tumor (MRT) (3, 4) , a highly aggressive neoplasm affecting renal or extra-renal soft tissue and cerebral tissue in pediatric patients. Previously published studies indicate that SMARCB1/INI1 gene is involved in the control of genomic stability and in the regulation of cell cycle progression (5) . SMARCB1 stimulates the p16/Rb tumor suppressor pathway by activation of CDKN2A and inhibition of Cdk/CyclinD (6) . As a result, in MRT cell lines it has been demonstrated that SMARCB1 loss is associated with responsiveness to Cdk/Cyclin inhibitors, such as 4-HPR (7) and Flavopiridol (8) . In addition, the in vivo spontaneous tumorigenesis in
SMARCB1
+/-knock-out mice is increased by TP53 null genetic background (9) and is prevented by CCND1 ablation (10) , further supporting the interaction with crucial molecules controlling cell cycle progression.
We first reported evidence of SMARCB1 inactivation in ES (11) , an event frequently associated with homozygous gene deletions (12) . The relevance of SMARCB1 in ES pathogenesis was then supported by other reports of subtle intragenic mutations, including small deletions and point mutations (13, 14) . Subsequent studies reported the occurrence of SMARCB1 protein and/or genetic alterations in ES ranging from 60% to 93% (12) (13) (14) (15) (16) . Although these differences may be attributable to the different molecular approaches undertaken to assess SMARCB1 inactivation, the lack of appropriate preclinical models for this enigmatic sarcoma subtype has so far prevented the assessment of the causal role in ES pathogenesis.
Here we provide evidence that the epithelioid sarcoma cell line VAESBJ carry a homozygous SMARCB1 deletion and that in this cell line SMARCB1 actually acts as a tumor suppressor.
Moreover, we provide evidence that SMARCB1 inactivation results in hyperactivation of ERBB1/EGFR and HGFR/MET pathways, thus disclosing novel avenues for the treatment of ES patients.
on 
MATERIALS AND METHODS
Cancer cell lines. VAESBJ was purchased from Interlab Cell Line Collection, Genova (Italy) and the other cell lines were from ATCC. Sarcoma subtypes represented were osteosarcoma (CRL1543/HOS; MG63), rhabdomyosarcoma (CRL7862/Hs729.T, CRL7726/T174, CRL7763/TE381.T), epithelioid sarcoma (VAESBJ, ATCC number CRL-2138), fibrosarcoma (HTB152/Hs913.T; MES-SA), leiomyosarcoma (HTB88/SK-LMS-1), renal rhabdoid sarcoma (G401) and renal leiomyoblastoma (G402). Hek293 and IMR90 are immortalized non-cancer cell lines originally derived from human embryonic kidney and fibroblasts, respectively. Cells were grown in RPMI 1640 supplemented with 10% heat-inactivated FBS, in a humidified incubator at 37°C and 5% CO 2 . Cell lines were authenticated regularly by microsatellite DNA fingerprinting. In order to establish the G402 and VAESBJ xenograft, 5x10 6 cells were injected subcutaneously in the flank of nude mice. After three weeks, the tumor was removed, formalin-fixed and processed as reported for immunohistochemistry analysis. For infection experiments, viral supernatants were prepared using pBabe-SMARCB1 (a kind gift by BE Weissman) and pBabe-control vectors using standard calcium-phosphate trasfection method in LynxA cells (17) . Supernatants were used for infection with polybrene 4 ug/ul by centrifugation at 1600 rpm for 1 h and over-night incubation at 32°C. Medium was then replaced and 48h later puromycin selection was started for 4 days. Bulk cell population was used in all experiments after 24h recovery from antibiotic selection. For transfection experiments, cells were transfected using the Dharmafect Transfection Reagent (Thermo Scientific) according to the instructions of the manufacturer and CCND1 was silenced in VAESBJ cell line using CCND1 siRNA (s229 Ambion) and compared with off-target control siRNA (AM4611 Ambion Total RNA was extracted using Trizol reagent (Ambion) and 1 μg RNA was retro-transcribed using Superscript II reverse transcriptase (Gibco) with random primers. Ten nanograms of cDNA were used as template in 20 μl PCR reactions with 1x TaqMan Universal PCR master mix (Applera).
Relative quantification of gene expression was performed in triplicate using TaqMan   Assays   on Demand on a ABI Prism 7900HT Sequence Detection System (Applera) by comparative Ct method, using the HPRT gene (HPRT PDAR, 4326321E) as endogenous reference control and 293 cell line as calibrator. SMARCB1 assay used was Hs00268260_m1, encompassing exons 4-5.
Mutational analysis. Mutational analysis was performed by exon amplification and sequencing as previously described (11) . For Multiplex ligation-dependent probe amplification (MLPA), tumor DNA (100 ng) was subjected to DNA copy number analysis using MLPA kits P258-B1, P294-A1 Anchorage-independent growth. Cells (10 5 ) were resuspended in 0.35% agar complete medium and seeded on 0.5% bottom agar medium in 6 cm petri dishes. After two weeks, plates were stained with iodonitrotetrazolium violet (1mg/ml, Sigma) and clones were counted at the microscope. Caspase 3/7 Assay. Caspase 3/7 Activity was assessed using Caspase-Glo 3/7 assay (Promega).
Cells were irradiated in suspension using a Gammacell 1000 Elite biologic irradiator (Nordion Inc), plated in 96 white-walled plates and analyzed after 48h. Caspase 3/7 GLO Reagent was added to each well and gently mixed for 1 minute. The luminescence of each sample was measured with a plate-reading luminometer 30 minutes after staining. As a control, all samples analyzed were plated also in a 96 multiwell and stained with SRB, as indicated above. To take into account the different proliferation between SMARCB1-expressing and control cells the measured Caspase-Glo 3/7 assay luminescence was normalized over SRB absorbance values. 
SMARCB1 loss sustains VAESBJ tumorigenic properties. In order to establish the relevance of SMARCB1 inactivation in VAESBJ cell line, we reintroduced SMARCB1 via retroviral infection ( Figure 3A) . After virus infection, cells were selected and the bulk cell population was analyzed for cell proliferation, cell cycle distribution, senescence, anchorage-independent growth and cell migration. For comparison, selected experiments were performed in parallel in G401 malignant rhabdoid tumor cell line (Supplemental Figure 3) , which was previously reported to be affected by SMARCB1 restoration (7, 8, 20) .
Ectopic SMARCB1 expression significantly reduced cell proliferation without affecting the extent of spontaneous cell death, as assessed by trypan blue staining (p= 0.019, 0.014 and 0.004 at 24h, 48h
and 72 h respectively, two-way Anova p< 0.001 for global trend, Figure 3B ). The observed reduction in cell proliferation correlated with a reduction of cells in S and G2/M-phases and an increase in the G0/G1-phase, as assessed by flow citometry ( Figure 3C ). Concordantly, BrdU incorporation and clonogenic potential were reduced in SMARCB1 engineered cells (p= 0.025, Figure 3D and p= 0.001, Figure 3E respectively). Also anchorage-independent growth was reduced in SMARCB1 re-expressing VAESBJ cells (p= 0.019, Figure 3F ), in part likely as a result of impaired proliferation. Different from the rhabdoid cell line G401, the ectopic expression of SMARCB1 in VAESBJ failed to result in the induction of premature senescence, as determined by SA--gal staining (Supplemental Figure 3) . Moreover, similar to what was described for rhabdoid cell lines (21) , SMARCB1 re-expression significantly reduced VAESBJ cell migration, as assayed by transwell chamber assay (p< 0.001, Figure 3G and Supplemental Figure 3) . Concordant with the observed reduction of anchorage-independent growth, also in-vivo tumorigenesis was significantly reduced and tumors grown were significantly smaller in SMARCB1 re-expressing VAESBJ cells (p< 0.0001 and p= 0.036 respectively, Figure 3H ).
SMARCB1 restoration sensitizes VAESBJ cell line to irradiation. The SWI/SNF chromatin remodelling complex and SMARCB1 itself have been reported to influence the response to DNA damage (22) . We here demonstrate that SMARCB1 re-expression increased sensitivity to gamma irradiation in VAESBJ cell line. Reduced cell viability (p= 0.039, 0.045, 0.02 at 200, 400 and 800 rad respectively, two-way Anova p= 0.085, Figure 4A ) and increased cell death (p= 0.001, 0.013, 0.002, 0.02 at 100, 200, 400 and 800 rad respectively, two-way Anova p= 0.008, Figure 4B ) were associated with increased of Caspase 3/7 activity (p= 0.014 at 1200 rad, Figure 4C ) and caspasemediated protein cleavage ( Figure 4D ). The enhanced SMARCB1-mediated sensitization to Figure 5F ), suggesting the presence of a synergistic effect.
To gain insights on the oncogenic pathways underlying VAESBJ tumorigenic phenotype that can be exploited for targeted therapeutic interventions, we performed phospho-protein array analyses. (Figure 6A ), that in turn impinge on AKT and ERK phosphorylation ( Figure 6B ). Although VAESBJ does not carry EGFR mutation, it displayed sustained, EGFR-independent, phospho-AKT activation and showed limited response to EGFR inhibition (32) . We found that the HGFR/MET pathway cooperates with EGFR in sustaining AKT and ERK phosphorylation.
These assays identified significant expression of activated/phosphorylated ERBB1/EGFR and
HGFR/MET
Pharmacological inhibition of HGFR/MET
Concordantly, combined inhibition of ERBB1/EGFR and HGFR/MET pathways resulted in enhanced and synergic growth suppression. Thus, our observations provide an explanation for the incomplete response of VAESBJ cell line to EGFR inhibition (32) .
Similar to MRTs cell lines (7, 10) , Flavopiridol treatment in VAESBJ induced both CCND1 protein downmodulation and cell cycle arrest. Unexpectedly, we observed a synergistic effect on cell cycle block with combined Flavopiridol treatment and SMARCB1 ectopic re-expression, indicating that Flavopiridol affects cell proliferation and viability through pathways at least in part independent of SMARCB1 tumor suppressor.
The cancer genome of pediatric MRTs is extraordinarily stable and the only recurrent alteration reported so far is SMARCB1 inactivation (33) , demonstrating that in specific cellular contexts unique genetic alterations are sufficient to sustain tumorigenesis. In contrast, epithelioid sarcoma (11, 34) and VAESBJ ES model system (35) (see also http://www.sanger.ac.uk/cgibin/genetics/CGP/cghviewer/CghHome.cgi), despite the shared feature of recurrent SMARCB1 inactivation, demonstrate a much more unstable genome, thus suggesting that in the adult setting the cancer-initiating cell of epithelioid sarcoma requires the overriding of multiple pathways, including the one involved in the control of genome integrity.
The p16/CCND1/CDK4/RB/E2F pathway inactivation has been initially reported as the prominent downstream effect of SMARCB1 inactivation in MRTs (20, 30, 36) . However, more recently, engineered mouse models demonstrated that SMARCB1 haploinsufficiency cooperates with both RB and TP53 haploinsufficiency to increase penetrance and reduce latency of tumor onset (9, 22, 37) and in-vitro studies showed that SMARCB1 inactivation globally affects the epigenetic status of the cancer genome (38, 39) . We observed that VAESBJ cells retain a wild-type TP53 but carry a homozygous deletion of CDKN2A locus, thus displaying impaired p16/RB and p14/TP53 responses. Overall, these data suggest that SMARCB1 collaborates with the inactivation of both TP53 and RB signals to promote tumorigenesis by, at least in part, independent pathways.
A previous report described the involvement of SMARCB1 in the modulation of DNA repair after UV irradiation (40) . We here demonstrate that indeed SMARCB1 inactivation is responsible for resistance to gamma irradiation and its restoration significantly augments the apoptotic response to irradiation-induced DNA damage.
In conclusion, we provide the first characterization of a cell model of epithelioid sarcoma carrying genetic inactivation of SMARCB1 by homozygous gene deletion. Our observations provide 
